Skip to content
10-K

Annual Report

MADRIGAL PHARMACEUTICALS, INC. MDGL

0001628280-26-009514

← back to feed
Filed
Feb 19, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 12, 2026 22.94M sh
Shares Diluted FY 2025 · Dec 31, 2025 22.43M sh
Shares Diluted FY 2025 · Dec 31, 2024 21.27M sh
Shares Diluted FY 2025 · Dec 31, 2023 18.69M sh
Capex FY 2025 · Dec 31, 2025 $467K
Capex FY 2025 · Dec 31, 2024 $1.46M
Capex FY 2025 · Dec 31, 2023 $1.48M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$189.55M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$455.57M
Operating Cash Flow FY 2025 · Dec 31, 2023 −$324.23M
Long Term Debt FY 2025 · Dec 31, 2025 $339.88M
Long Term Debt FY 2025 · Dec 31, 2024 $117.57M
Cash And Equivalents FY 2025 · Dec 31, 2025 $198.69M
Cash And Equivalents FY 2025 · Dec 31, 2024 $100.02M
Stockholders Equity FY 2025 · Dec 31, 2025 $602.69M
Stockholders Equity FY 2025 · Dec 31, 2024 $754.38M
Stockholders Equity FY 2025 · Dec 31, 2023 $405.33M
Current Liabilities FY 2025 · Dec 31, 2025 $310.29M
Current Liabilities FY 2025 · Dec 31, 2024 $169.28M
Total Liabilities FY 2025 · Dec 31, 2025 $656.9M
Total Liabilities FY 2025 · Dec 31, 2024 $287.86M
Current Assets FY 2025 · Dec 31, 2025 $1.25B
Current Assets FY 2025 · Dec 31, 2024 $1.03B
Total Assets FY 2025 · Dec 31, 2025 $1.26B
Total Assets FY 2025 · Dec 31, 2024 $1.04B
Eps Diluted FY 2025 · Dec 31, 2025 −$12.85
Eps Diluted FY 2025 · Dec 31, 2024 −$21.90
Eps Diluted FY 2025 · Dec 31, 2023 −$19.99
Eps Basic FY 2025 · Dec 31, 2025 −$12.85
Eps Basic FY 2025 · Dec 31, 2024 −$21.90
Eps Basic FY 2025 · Dec 31, 2023 −$19.99
Sga Expense FY 2025 · Dec 31, 2025 $813.83M
Sga Expense FY 2025 · Dec 31, 2024 $435.06M
Sga Expense FY 2025 · Dec 31, 2023 $108.15M
Net Income FY 2025 · Dec 31, 2025 −$288.28M
Net Income FY 2025 · Dec 31, 2024 −$465.89M
Net Income FY 2025 · Dec 31, 2023 −$373.63M
Operating Income FY 2025 · Dec 31, 2025 −$300.1M
Operating Income FY 2025 · Dec 31, 2024 −$497.88M
Operating Income FY 2025 · Dec 31, 2023 −$380.5M
Revenue FY 2025 · Dec 31, 2025 $958.4M
Revenue FY 2025 · Dec 31, 2024 $180.13M
Revenue FY 2025 · Dec 31, 2023 $0